Lansoprazole Cristers

Lansoprazole, the active ingredient in Lansoprazole Cristers, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and Helicobacter pylori infection.

GNH USA supplies Lansoprazole Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole is a proton pump inhibitor indicated for several acid‑related gastrointestinal disorders.

Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and promotes healing of the esophageal lining. Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. Helicobacter pylori eradication: used in combination therapy to improve bacterial clearance. Erosive esophagitis: decreases acid‑induced damage and supports mucosal recovery.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea: may occur after dosing. - Abdominal pain or discomfort.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty. - Low magnesium levels (hypomagnesemia): can cause muscle cramps, arrhythmias.

Before initiating therapy, consider the following precautions.

Assess renal function: adjust use in severe impairment. Monitor for drug interactions: especially with clopidogrel and antiretrovirals. Use caution in elderly patients: higher fracture risk with long‑term use. Avoid abrupt discontinuation: may cause rebound acid hypersecretion. Store at room temperature: keep in the original pack, protect from moisture.

Lansoprazole may interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: may raise serum concentrations. - Methotrexate: risk of increased toxicity, especially at high doses.